Search Count: 5
![]() |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.95 Å Release Date: 2022-12-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XTM |
![]() |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.90 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XTJ |
![]() |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.85 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XTP |
![]() |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.93 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XU4 |
![]() |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.00 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XV4 |





